HMGB1-antagonism exerted by glycyrrhizin could be fruitful against COVID-19.
Keywords:
COVID-19, SARS CoV-2, HMGB1, Glycyrrhizin, Prophylaxis.Abstract
The COVID-19 pandemic era is causing a relevant issue for the health. There is no specific drug able to antagonize the SARS-CoV-2 infection. As a consequence, there is growing interest about potential molecules able to contrast infection. In this regard, HMGB, an alarmin, may play a relevant role in pathogenic mechanisms induced by SARS-CoV-2. As HMGB1 is antagonized by glycyrrhizin, this substance could be potentially useful as ancillary treatment in COVID-19.References
WHO Coronavirus (COVID-19) Dashboard. https://covid19.who.int
Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review. JAMA 2020;324(8):782-793
Marmitt DJ, Goettert MI, Rempel C. Compounds of plants with activity against SARS-CoV-2 targets. Expert Rev Clin Phrmacol 2021 (in press)
Omrani M, Keshavarz M, Ebrahimi SN, Mehrabi M, McGraw LJ, Abdalla MA, et al. Potential natural products against respiratory viruses. A prespective to develop anti-COVID-19 medicines. Frontiers Pharmacol 2021;11:586993
Qu L, Chen C, Chen Y, Li Y, Tang F, Huang H, et al. High-mobility group box 1 (HMGB1) and autophagy in acute lung injury (ALI): a review. Med Sci Monit 2019;25:1828-1837
Yang H, Wang H, Andersson U. Targeting inflammation driven by HMGB1. Frontiers Immunol 2020;11:484
Andersson U, Ottestad W, Tracey KJ. Extracellular HMGB1: a therapeutic target in severe pulmonary inflammation including COVID-19? Mol Med 2020;26:42
Chiappalupi S, Salvadori L, Vukasinovic A, Donato R, Sorci G, Riuzzi F. Targeting RAGE to prevent SARS-CoV-2-mediated multiple organ failure: hypotheses and perspectives. Life Sci 2021;272:119251
Chen R, Huang Y, Quan J, Liu J, Wang H, Billiar TR, et al. HMGB1 as a potential biomarker and therapeutic target for severe COVID-19. Heliyon 2020;6:e05672
Bailly C, Vergoten G. Glycyrrhizin: an alternative drug for the treatment of COVID-19 infection and the associated respiratory syndrome? Pharmacol Therap 2020;214:107618
Kwon YJ, Son DH, Chung TH, Lee YJ. A review of the pharmacological efficacy and safety of Licorice root from corroborative clinical trial findings. J Med Food 2010;23.1-9
Richard SA. Exploring the pivotal immunomodulatory and anti-inflammatory potentials of glycyrrhizic and glycyrrhetinic acids. Mediators Inflamm 2021;6699560
El-Saber Batiha G, Beshbishy AM, El-Mleeh A, Abdel-Daim MM, Prasad Devkota H. Traditional uses, bioactive chemical constituents, and pharmacological and toxicological activities of Glycyrrhiza glabra L. (Fabaceae). Biomolecules 2020;10:352
Murck H. Symptomatic protective action of glycyrrhizin (Licorice) in COVID-19 infection? Frontiers Immunol 2020;11:1239
Luo P, Liu D, Li J. Pharmacological perspective: glycyrrhizin may be an efficacious therapeutic agent for COVID-19. Int J Antimicrob Agents 2020;55.105995
Downloads
Published
Issue
Section
License
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Transfer of Copyright and Permission to Reproduce Parts of Published Papers.
Authors retain the copyright for their published work. No formal permission will be required to reproduce parts (tables or illustrations) of published papers, provided the source is quoted appropriately and reproduction has no commercial intent. Reproductions with commercial intent will require written permission and payment of royalties.
How to Cite
